Annovis Bio, Inc. - 10-Q Filing
Annovis Bio filed its Q1 2026 10-Q report with the SEC on May 15, 2026. The filing includes unaudited financial statements showing a decrease in cash from $19.5 million as of December 31, 2025 to $14.2 million as of March 31, 2026. Total liabilities increased to $13.1 million compared to $4.2 million at year-end 2025 due primarily to a rise in current liabilities from accounts payable and accrued expenses.
Tickers: $ANVS